Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

Currently the manufacturers of zoledronic acid, also called zoledronate, recommend a once-yearly intravenous infusion of 5 milligrams (mg) for prevention of fractures in people with osteoporosis.

Three thousand three hundred sixty women with stage II or III breast cancer were randomly assigned to receive standard adjuvant systemic therapy alone or with zoledronate administered at a dose of 4 ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — One-fifth or half of the currently recommended dose of zoledronic acid may be sufficient to reduce the ...

Bone is one of the most frequent sites for metastasis in breast cancer patients often resulting in significant clinical morbidity and mortality. Bisphosphonates are currently the standard of care for ...

As with all medications, the cost of zoledronic acid can vary. Factors that may affect the price you’ll pay include your treatment plan and your insurance coverage. It may also depend on the cost of ...